NEW HAVEN, CT--(Marketwired - July 20, 2016) - Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") reported today that the Company has begun dosing subjects in its first clinical trial to evaluate the safety and … Read More»

NEW HAVEN, CT--(Marketwired - July 05, 2016) - Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company's investigational new … Read More»

New Haven, Connecticut (PRWEB) May 25, 2016 -Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug designation request covering BHV-4157 for the … Read More»

New Haven, Connecticut (PRWEB) May 9, 2016 – The Board of Directors of Biohaven Pharmaceutical Holding Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of Jim Engelhart, CPA as its Chief Financial Officer. Mr. Engelhart joins … Read More»

British Virgin Islands (PRWEB) April 27, 2016 – The Board of Directors of Biohaven Pharmaceutical Holding Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven … Read More»

  We were pleased to be mentioned in alsnewstoday.com. ALS News Today is a daily digital news journal that seeks to give ALS patients and their support systems access to the latest science and research news pertaining to the disease. Click … Read More»

Company Receives Orphan Drug Designation Request for Spinocerebellar Ataxia Covering BHV-0223   British Virgin Islands (PRWEB) March 3, 2016 - Biohaven Pharmaceutical Holding Company Ltd. (d/b/a Biohaven) announced today that the Food and Drug … Read More»

Company Plans for Timely Completion of Bioequivalence Study and NDA Submission British Virgin Islands (PRWEB) February 25, 2016 - Biohaven Pharmaceutical Holding Company Ltd.(d/b/a Biohaven) announced receiving favorable and productive feedback from … Read More»

British Virgin Islands (PRWEB) February 24, 2016 — Biohaven Pharmaceutical Holding Company Limited (d/b/a Biohaven) announced today positive results from a Phase I study with BHV-0223, a glutamate modulating agent. The final study results … Read More»

Biohaven Pharmaceutical Holding Company Limited (d/b/a Biohaven) announced today that preliminary results from a Phase I study with BHV-0223, a glutamate modulating agent, met its study objectives and supports advancing the asset into late phase … Read More»